Figure 1.

Waterfall plot of response to durvalumab plus tremelimumab. Of four patients with more than 30% reduction in tumor measurements, two had documented responses in the primary resistance cohort (1 partial and one complete response). One patient in the primary resistance cohort was found to have stable disease on independent radiology review. One patient in the acquired resistance cohort stopped treatment before disease progression (best response of stable disease) and started a new treatment prior to subsequent tumor measurements (included above).